Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Janssen
Press release submission
| Dec 29, 2021
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Press release submission
| Dec 22, 2021
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
Press release submission
| Aug 19, 2021
Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Jan 16, 2019
JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
Press release submission
| Dec 6, 2018
JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Trending
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
Researchers Look for Long-Term Hearing Loss Treatments
+
Pharmaceuticals
Patient Daily
| Apr 25, 2024
"My Future Depends on It:" Local Teacher Raises Nearly $95,000 for Lung Cancer Research
+
Pharmaceuticals
Patient Daily
| Apr 24, 2024
American Lung Association Report: Utah Receives Poor Grades for Ozone and Particle Pollution
+
Pharmaceuticals
Patient Daily
| Apr 25, 2024
Labor and delivery nurse overcomes cancer and heart failure